Literature DB >> 2061146

Costs of veterinary services and vaccines/drugs used for prevention and treatment of diseases in 60 Tennessee cow-calf operations (1987-1988).

J C New1.   

Abstract

Four percent of the total cost of disease in 60 Tennessee cow-calf herds in 1987 to 1988 was attributable to veterinary services, and 2.3% was attributable to the purchase of drugs to treat sick animals. When producers spent money on therapeutic veterinary services, it was most often attributable to diseases of the reproductive system ($0.69/cow annually), especially dystocia ($0.51/cow annually). When drugs were used therapeutically, the most was spent on products to treat respiratory tract disease ($0.37/cow annually). The cost of preventive veterinary services accounted for 8.8% of the total cost of preventive actions. Pregnancy examinations (considered here as a preventive action) was the most costly preventive service ($0.62/cow annually). The cost of drugs and biologicals used to prevent disease accounted for 69.4% of the total cost of preventive actions, with drugs to prevent intestinal and external parasites being the most costly ($7.79/cow annually). These figures are based on cow-calf herds randomly selected by use of a 2-stage, stratified plan. Herds were visited once a month for 1 year. Results of this study support other work that showed that beef producers perceive veterinarians as primary sources of information on diagnosis and treatment of sick animals and on reproduction/breeding, but less knowledgeable or cost effective in the areas of animal/herd management, feed nutrition, and agribusiness/economics.

Entities:  

Mesh:

Year:  1991        PMID: 2061146

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  1 in total

1.  Characterization of hemolysin of Moraxella bovis using a hemolysis-neutralizing monoclonal antibody.

Authors:  F M Billson; C Harbour; W P Michalski; J M Tennent; J R Egerton; J L Hodgson
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.